HELLO OUT THERE>>>>>>>>>>>
News today:
Repro-Med Systems Announces Medicare Approval of Res-Q-Vac
Airway Suction System
November 14, 2000 9:30am
Source: Business Wire
CHESTER, N.Y., Nov 14, 2000 (BUSINESS WIRE) -- Repro-Med Systems Inc.
(OTCBB:REPR) has been notified by Health Care Financing Administration
(HCFA) that its Res-Q-Vac Oral Vacuum Suction System has been
approved for reimbursement for home-care use under miscellaneous durable
medical equipment code E1399.
The sterile catheters are approved for tracheal suction, code A4624, and
for oropharyngeal suction, code A4628. The Res-Q-Vac is a hand-operated,
portable, lightweight suctioning device and can be used at home for
suctioning patients with tracheotomies, swallowing disorders, excessive
fluid or phlegm, Cerebal Palsy and any time suction is needed in the
naso-pharynx. The Res-Q-Vac is totally portable and non-electric,
providing complete mobility.
"The use of the Res-Q-Vac at home represents tremendous value and
efficacy to patients in home care," commented Andy Sealfon, president of
Repro-Med Systems Inc. "While patients get the benefit of portability and
quality of care, insurance carriers will appreciate the huge reduction in the
cost of providing suction equipment to these patients. This market is
potentially larger than the Emergency Medical Market we are presently
selling due to the actual amount of suctioning done in the home."
Typical costs of conventional electric suction run in the hundreds of
dollars, while the home-care version of the Res-Q-Vac complete with sterile
catheters and vial is priced at less than $80.
For further information, visit the company's Web site at
repro-med.com.
THIS news release contains certain "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995) and
information relating to Repro-Med Systems Inc. that are based on the
beliefs of the management of Repro-Med Systems Inc. as well as
assumptions made by and information currently available to the
management of Repro-Med Systems Inc. The company's actual results may
vary materially from the forward-looking statements made in this report due
to important factors such as: recent operating losses; uncertainties
associated with future operating results; unpredictability related to Food
and Drug Administration regulations; introduction of competitive products;
limited liquidity; reimbursement-related risks; government regulation of the
home health-care industry; success of the research and development
effort; market acceptance of FREEDOM60; availability of sufficient capital
to continue operations; and dependence on key personnel. When used in
this news release, the words "estimate," "project," "believe," "anticipate,"
"intend," "expect" and similar expressions are intended to identify
forward-looking statements. Such statements reflect the current views of
Repro-Med Systems Inc. with respect to future events based on currently
available information and are subject to risks and uncertainties that could
cause actual results to differ materially from those contemplated in such
forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. Repro-Med does not undertake any obligation to release
publicly any revision to these forward-looking statements to reflect events
or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
CONTACT: Repro-Med Systems Inc., Chester
Andy Sealfon, 914/469-2042 |
